The medicinal cannabis company Zelda Therapeutics Ltd (ASX: ZLD) hit the ASX boards following its successful reverse takeover of Gleneagle Gold. According to its prospectus the company aimed to raise $4 million from the listing that will be used to fund initial phase 2 clinical trials. Management has its eyes on the potentially lucrative sleep disorder, wound care, breast cancer, and skin disorder treatment markets.

WKN: - ISIN: AU000000ZLD1 Kürzel: CANN (OTC)   in  handelbar: JA

Gründungsjahr: 1987 Haupthandelsplatz  Vollzogene Namenswechsel Gleneagle Gold 10/2016 Land   Angestellte: 6